Inhibiting microRNA-449 Attenuates Cisplatin-Induced Injury in NRK-52E Cells Possibly via Regulating the SIRT1/P53/BAX Pathway

Wen Qin* Wei Xie* Xi Yang Ning Xia Kunling Yang

* These authors contributed equally to this work

Corresponding Author: Ning Xia, e-mail: xianing2693@126.com

Source of support: Supported by the National Natural Science Foundation of China (No. 81060070) and the Health Department self-raised funds projects of Guangxi Province (No. Z2014056)

Background: Acute kidney injury (AKI) is quite common in the patients who frequently use the anticancer drug cisplatin. microRNAs (miRNAs) are powerful tools in modulating the expression of key factors in disease progression, but little is known about roles of miRNAs in AKI. This study explored the expression and function of miR-449 in cisplatin-induced AKI.

Material/Methods: Rat renal proximal tubular cell line NRK-52E was used for cisplatin treatment and miR-449 sponge transfection. MTT assay and flow cytometry were performed to detect cell viability and apoptosis in different cell groups. Protein expression of sirtuin 1 (SIRT1), acetylated p53, and BCL-associated X protein (BAX) was detected to deduce the possible regulatory mechanism of miR-449.

Results: Results showed that cisplatin treatment in NRK-52E cells significantly up-regulated miR-449 levels (P<0.05), inhibited cell viability (P<0.05), accelerated cell apoptosis (P<0.05), and changed SIRT1, acetylated p53, and BAX protein levels (P<0.01). However, inhibiting miR-449 by its sponge transfection in cisplatin-treated cells significantly promoted cell viability (P<0.05), suppressed cell apoptosis (P<0.05), elevated SIRT1 expression (P<0.01), and inhibited acetylated p53 and BAX protein levels (P<0.001).

Conclusions: These results indicate that inhibiting miR-449 allows the attenuation of cisplatin-induced injury in NRK-52E cells, suggesting that miR-449 is a potential target for treating AKI. miR-449 regulates the SIRT1/p53/BAX pathway, which may be its possible mechanism in modulating cell apoptosis of cisplatin-induced AKI. Further verification and a thorough understanding are necessary for targeting miR-449 in AKI treatment.

MeSH Keywords: Acute Kidney Injury • Apoptosis • Cisplatin • MicroRNAs • Sirtuin 1

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/897187
Background

Acute kidney injury (AKI) is a series of clinical syndromes defined as increase in serum creatinine (Scr) by over 26.5 μM within 48 h, or increase in Scr to over 1.5 times baseline occurring within the prior 7 days, or urine volume less than 0.5 mL/kg/h for 6 h [1]. It is usually accompanied by oliguria, electrolyte imbalance, metabolic acidosis, azotemia, and other clinical manifestations. AKI can be divided into 3 categories according to the pathology: prerenal, intrinsic, and postrenal AKI. Moleular markers, such as cystatin C, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and interleukin-18, play important roles in the diagnosis of AKI [2-4]. Feasible treatment methods include the use of drugs like fentodopam [5], and blood purification therapy such as peritoneal dialysis [6], intermittent renal replacement therapy [7], and continuous renal replacement therapy [8].

Cisplatin is a broad-spectrum anticancer drug widely used in the clinical treatment of diseases such as ovarian cancer, testicular cancer, lung cancer, esophagus cancer, and malignant lymphoma. It crosslinks with DNAs and thereby inhibits DNA replication and transcription [9]. Efforts have been made to improve the sensitivity of tumor cells to cisplatin treatment [10,11]. However, a difficult problem is the adverse effect of cisplatin in normal tissues, causing nephrotoxicity, myelosuppression, anaphylaxis, and neurotoxicity [12], severely limiting the clinical use of cisplatin. The impacts of cisplatin on the kidneys are mainly manifested in the apoptosis of renal tubular cells, because cisplatin induces endoplasmic reticulum stress, activates the apoptotic pathways (including the death receptor pathway and mitochondrial pathway), and leads to caspase-3 activation and reactive oxygen species induced by cisplatin also aggravate AKI [14,15].

microRNAs (miRNAs) are small endogenous RNA molecules that recognize specific target sequences, thus regulating mRNA stability and translation activity. Recent findings have reported the vital roles of miRNAs in modulating key factors in AKI. miR-34, miR-125b, and miR-127 are confirmed to play protective roles in the context of AKI, while miR-21, miR-29, and miR-192 are involved in the progression of renal fibrosis [16]. miR-21 is an especially promising biomarker for diagnosing and treating AKI because of its association with cell apoptosis, and inflammatory and fibrotic pathways [17]. From this point of view, research in miRNAs is of great value for a better understanding of and novel therapeutic strategies for AKI.

A recent study has indicated that miR-449 is almost absent in the kidneys [18], but its expression during AKI remains uncertain. This study investigated the expression pattern and roles of miR-449 in cisplatin-induced AKI. Rat renal proximal tubular cell line NRK-52E was used to stimulate AKI in vitro by cisplatin treatment, and then miR-449 was inhibited by its sponge transfection. The changes in cell viability and apoptosis induced by cisplatin and miR-449 inhibition were detected by MTT and flow cytometry. This study also investigated the regulatory mechanism of miR-449 in AKI by detecting expression of its possible target sirtuin 1 (SIRT1) and downstream factors tumor protein p53 and BCL2-associated X protein (BAX). These results may provide an overview of miR-449 in cisplatin-induced AKI and offer a potential therapeutic target for treating this disease.

Material and Methods

Cell model

Rat renal proximal tubular cell line NRK-52E (Institute of Biochemistry and Cell Biology, Shanghai, China) was cultured in Dulbecco’s modified Eagle medium/F12 (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco) in a humidified atmosphere with 5% CO₂ at 37°C. Cells were first divided into 2 groups: the cisplatin-induced renal injury model group and the control group. Cells of the cisplatin group were treated with 20 μg/mL cisplatin (Abcam, Cambridge, UK) for 24 h before cell transfection.

Transfection

The cisplatin-treated cells were seeded in 6-well plates (1×10^6 per well) 1 day before transfection to 90% confluency. The cells were then divided into 3 groups: cisplatin (cisplatin-treated cells without transfection), cisplatin + blank vector (cisplatin-treated cells transfected with blank vector as a control), and cisplatin + miR-449 sponge (cisplatin-treated cells transfected with miR-449 sponge to inhibit miR-449). The cells were transfected with miR-449 sponge (2 μg/mL) or blank control synthesized by QuantoBio (Beijing, China) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruction. The medium was changed at 6 h after transfection, and cells were collected for further analysis at 48 h after transfection.

Cell viability assay

Cells in the logarithmic phase were collected for cell viabiliy assay by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method using MTT Cell Proliferation and Cytotoxicity Assay Kit (Beyotime, Shanghai, China) according to the manufacturer’s instructions. Briefly, 100 μL of cell suspension (5×10^4 cells) was added to each well of a 96-well plate, and 10 μL MTT buffer was added for a 4-h incubation at 37°C, after which 100 μL of Formazan dissolving solution was added for 30 min at 37°C, after which 100 μL of Formazan dissolving solution was added.
was added to each well. The plate was incubated until formazan dissolved. Then the optical density (OD) at 570 nm was measured using a microplate reader (Bio-Rad, Hercules, CA). OD of cisplatin, cisplatin + blank control, or cisplatin + miR-449 sponge groups was compared to that of the control group.

Cell apoptosis assay

Cell apoptosis was detected by flow cytometry after treatment using the Annexin V-FITC Apoptosis Detection Kit II (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. Briefly, cells were washed twice with cold phosphate-buffered saline (PBS) and resuspended in binding buffer. We added 100 μL of cell suspension (1×10⁵ cells) to each well of a 96-well plate, and 2 μL of Annexin V-FITC was added for a 15-min incubation on ice in the dark. Before detection, 400 μL of PBS and 1 μL of propidium iodide (PI) were added. Flow cytometry (BD Biosciences) was used to detect the FITC-positive and PI-negative cells (early apoptotic), which were regarded as apoptotic cells in the analyses.

qPCR

miRNAs of each cell group were isolated using RNAiso for Small RNA (TaKaRa, Dalian, China) according to the manufacturer’s instructions. A specific primer for mno-miR-449a-5p (5'-CTC AAC TGG TGT CGT GGA GTC GGC AAT TCA GTT GAG ACC AGC TA-3') was used in the reverse transcription catalyzed by PrimeScript Reverse Transcriptase (TaKaRa). miR-449 expression level in these cell groups was determined by quantitative real-time PCR on platform LightCycler 480 (Roche, Basel, Switzerland) with each reaction system containing 20-ng templates and the specific primers for mno-miR-449a-5p (Fw: 5'-ACA CTC CAG CTG GGC AGT GTA TTG TTA-3' and Rv: 5'-TGG TGT CGT GGA GTC G-3'), U6 (Fw: 5'-CTC GCC GTT CGT GCA CA-3' and Rv: 5'-AAC GCT TCA CGA ATT TGC GT-3') was used as an internal control. Data were analyzed with 2⁻ΔΔCt method.

Western blot

Protein samples of the 4 cell groups were extracted by lysis buffer (Beyotime). The protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with 20 μg of protein loaded in each lane. The protein on gel was transferred to a polyvinylidene fluoride membrane and blocked in 5% skim milk for 2 h at room temperature, after which the membrane was incubated in primary antibodies for SIRT1, acetylated p53, or BAX (ab110304, ab61241, ab32503, Abcam) overnight at 4°C. GAPDH (ab181602) was used as an internal control. After washing 3 times in PBS, the membrane was incubated in horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Signals were developed using the EasyBlot ECL Kit (Sangon Biotech, Shanghai, China), and the grey-scale value of tested proteins was analyzed using the ChemiDoc XRS System and compared to that of the GAPDH.

Statistical analysis

All the experiments were performed in triplicate. Results were indicated as the mean ± standard deviation. Data were analyzed using the t test and one-way ANOVA in SPSS 20. Differences were considered significant at P<0.05.

Results

miR-449 level is elevated after cisplatin treatment in NRK-52E cells

The expression level of miR-449 was detected by qPCR in the 4 cell groups (Figure 1). Compared to the control group, cisplatin induced significant up-regulation of miR-449 expression in NRK-52E cells (P<0.05), implying the possible relationship of miR-449 expression and the cisplatin-induced renal tubular cell injury, which inspired us to investigate the role of miR-449 by inhibiting its expression in renal cell injury. But before that, the inhibition of miR-449 by its sponge vector transfection
was verified to be effective, and results showed the miR-449 level after cisplatin treatment was significantly suppressed by its sponge compared to blank vector transfection ($P<0.05$). Therefore, these transfected NRK-52E cells were used in the following experiments.

**Inhibiting miR-449 promotes cell viability and suppresses cell apoptosis**

The changes in NRK-52E cells by miR-449 were analyzed from cell viability and apoptosis. MTT results indicated that cisplatin significantly inhibited cell viability compared to the control ($P<0.05$, Figure 2A), while miR-449 sponge transfection resulted in a recovery compared to the transfection control ($P<0.05$). The percentage of FITC-positive and PI-negative apoptotic cells were increased after cisplatin treatment ($P<0.05$, Figure 2B), and miR-449 sponge reduced the apoptotic cells compared to the transfection control ($P<0.05$). These data suggest that cisplatin had cytotoxicity in NRK-52E cells, influencing both cell viability and cell apoptosis, and that inhibiting miR-449 promoted cell viability and suppressed cell apoptosis, which might protect NRK-52E cells from cisplatin-induced renal tubular cell injury.

**miR-449 regulates SIRT1, p53 acetylation and BAX**

This study tried to investigate the possible mechanism of miR-449 in NRK-52E cells. miR-449 was predicted to target Sirt1 mRNA by online database microRNA.org-Targets and Expression (www.microrna.org), and some studies have indicated Sirt1 mRNA to be a direct target for miR-449 [19], so the protein expression of SIRT1 and its downstream p53 and BAX was detected by Western blot analysis (Figure 3A). Results showed that, as predicted, SIRT1 was inhibited after cisplatin treatment when miR-449 was up-regulated, and then it was promoted by miR-449 sponge transfection. Acetylated p53 and BAX showed the opposite changes; they were promoted by cisplatin treatment and then inhibited by miR-449 sponge. Repeated results of Western blot analysis indicated significant differences after cisplatin treatment or miR-449 sponge transfection ($P<0.01$ or $P<0.001$, Figure 3B). These data suggest that inhibiting miR-449 affects the expression of SIRT1, p53 acetylation and promote BAX expression, which might be a potential mechanism of miR-449 in cisplatin-induced renal tubular cell injury.

**Discussion**

miRNA research has become popular in AKI studies, but roles of miRNAs in cisplatin-induced AKI remain elusive. This study reveals the up-regulated miR-449 level in cisplatin-treated NRK-52E cells, and that inhibiting miR-449 reverses the pro-apoptotic effects of cisplatin on NRK-52E cells, and that miR-449 regulates SIRT1 and downstream p53 and BAX. As a widely-used antitumor drug in chemotherapy, cisplatin is generally found to have adverse effects, especially its nephrotoxicity, which promotes apoptosis of renal tubular cells. Results of this study indicated that cisplatin could up-regulate miR-449 expression and affect NRK-52E cells, both inhibiting the viability and intensifying the apoptosis. These *in vitro* results are in line with the adverse effects of cisplatin found in clinical treatment. Moreover, findings of this study establish a possible relationship between miR-449 level and cisplatin-induced cell injury, which needs further verification.
miR-449 expression was significantly up-regulated in cisplatin-treated NRK-52E cells compared to the untreated cells, and its inhibition was confirmed to promote cell viability and inhibit cell apoptosis of cisplatin-treated NRK-52E cells, implying the pro-apoptotic role of miR-449 in cisplatin-induced AKI. Similar results have been found in gastric cancer, where miR-449 inhibits cell proliferation and is down-regulated [19], and in prostate cancer with miR-449-induced cell cycle arrest [20]. In primary human bronchial epithelial cells exposed to volatile cigarette smoke, both miR-449 and its transcription factor EZF1 levels are increased, which may allow the elimination of cells with damaged DNA [21]. Taken together, the functions of miR-449 in various cell types and diseases are relatively conserved: its pro-apoptotic role helps to prevent cancer progression in cancer cells and aggravates injury degree in AKI, as found in this study.

SIRT1 is a direct target for miR-449 based on existed studies [19] and online prediction, so this study did not perform verification using luciferase report assay. It is generally considered that SIRT1 plays crucial roles in cisplatin-induced AKI, with its overexpression protects renal proximal tubular cells [22]. Tumor protein p53 functions as an apoptosis facilitator in various diseases, including kidney injury and carcinoma [23,24], as well as cisplatin-induced AKI, with its down-regulation attenuating the injury [25,26]. SIRT1 deacetylates p53, thus regulating cell apoptosis during kidney injury [27,28]. BAX is a downstream factor of p53 that indicates cell apoptosis in numerous studies [29]. Upon DNA damage, p53 induces BAX translocation to mitochondria and cytochrome C release is promoted accordingly [30,31], which is also one of the molecular mechanisms of renal cell apoptosis [32]. Thus, SIRT1/p53/BAX has an important role in signaling in the mitochondria apoptosis pathway.

Based on the above information that the mitochondria apoptosis pathway is one of the mechanisms in AKI, this study attempted to reveal the possible regulatory mechanism of miR-449 in AKI, and found that inhibiting miR-449 promoted SIRT1 expression and inhibited p53 acetylation and BAX expression, which were altered by cisplatin treatment in NRK-52E cells. It can be deduced that the cisplatin-induced miR-449 up-regulation inhibits SIRT1, which further elevates acetylated p53 and BAX levels, thus activating the p53/BAX signaling of the mitochondria apoptosis pathway. Therefore, miR-449 may be a promising target in AKI treatment. The regulation of the SIRT1/p53/BAX mitochondria apoptosis pathway may be a potential functioning mechanism of miR-449 in cell apoptosis of cisplatin-induced AKI. However, more verification is necessary to confirm the direct association between miR-433-regulated SIRT1/p53/BAX signaling and cisplatin-induced AKI. It is possible that miR-449 targets other factors, such as histone deacetylases [33], and affects brain development, spermatogenesis and multiciliogenesis [34–36]. Therefore, a comprehensive understanding of the miR-449-involved regulatory network is indispensable for its application to AKI clinical treatment.
Conclusions

Our study indicates that inhibiting miR-449 in cisplatin-treated NRK-52E cells attenuates the affected cell viability and promoted cell apoptosis caused by cisplatin, indicating miR-449 is a potential therapeutic target for treating AKI. In addition to the possible SIRT1/p53/BAX signaling regulated by miR-449, more thorough information on the mechanism will be helpful for future research.

Conflict of interests

No conflict of interests exists.

References:

1. Kellum JA, Lameire N: Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care, 2013; 17: 204–18
2. Takeuchi T, Isobe S, Sato K et al: Cystatin C: A possible sensitive marker for detecting potential kidney injury after computed tomography coronary angiography. J Comput Assist Tomogr, 2011; 35: 240–45
3. Ko GL, Grigorey ON, Linfert D et al: Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. Am J Physiol Renal Physiol, 2010; 298: F1472–83
4. Parikh CR, Mishra J, Thiessen-Philbrook H et al: Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int, 2006; 70: 199–203
5. Nielsen LK, Bracker K, Price LL: Administration of fenoldopam in critical illness in small animal patients with acute kidney injury: 28 dogs and 34 cats (2008–2012). J Vet Emerg Crit Care, 2015; 25: 396–404
6. Chionh CY, Soni SS, Finkelstein FO et al: Use of peritoneal dialysis in AKI: A systematic review. Clin J Am Soc Nephrol, 2013; 8: 1649–60
7. Lins RL, Elseviers MM, Van der Niepen P et al: Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: Results of a randomized clinical trial. Nephrol Dial Transplant, 2009; 24: 512–18
8. Gibney N, Hoste E, Burdmann EA et al: Timing of initiation and discontinuation of renal replacement therapy in AKI. Unanswered key questions. Clin J Am Soc Nephrol, 2008; 3: 876–80
9. Jamieson ER, Lppard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev, 1999; 99: 2467–98
10. Lei Y, Hu X, Li B et al: miR-150 regulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit, 2014; 20: 1850–57
11. Damia G, Colella G, Sire EAG, Broggini M: Response to UV and cisplatin-induced damage in human ovarian cancer cells overexpressing XBP1 and expressing or not a wild type p53. Med Sci Monit, 1999; 5: BR815–20
12. Lorito G, Hatzopoulos S, Laurell G et al: Dose-dependent protection on cisplatin-induced ototoxicity – an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med Sci Monit, 2011; 17(B): BR179–86
13. Pabla N, Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int, 2008; 73: 994–1007
14. Faubel S, Lewis EC, Reznikov L et al: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther, 2007; 322: 8–15
15. Palab A, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis, 1997; 29: 465–77
16. Khalid U, Bowen T, Fraser DJ, Jenkins RH: Cisplatin kidney injury: A paradigm for miRNA regulation of the cell cycle. Biochem Soc Trans, 2014; 42: 1219–23
17. Li YF, Jing Y, Hao J et al: MicroRNA-21 in the pathogenesis of acute kidney injury. Protein Cell, 2013; 4: 83–19
18. Kito N, Endo K, Ikuse M et al: miRNA Profiles of tubular cells: Diagnosis of kidney injury. Biomed Res Int, 2015; 2015: 465479
19. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A et al: miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer, 2011; 10: 29
20. Noonan EJ, Place RF, Basak S et al: miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget, 2010; 1: 349–58
21. Herr C, Lize M, Klimke A et al: MicroRNA-21 is a new marker of differentiation and repair in bronchial epithelial cells. American Journal of Respiratory & Critical Care Medicine, 2011; 183
22. Hasegawa K, Waki S, Yoshikawa K et al: Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem, 2010; 285: 13045–56
23. Ku BM, Kim DS, Kim KH et al: Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J, 2013; 27: 3487–95
24. Sutton TA, Hato T, Mai E et al: p53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol, 2013; 24: 113–24
25. Jiang M, Dong Z: Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther, 2008; 327: 300–7
26. Molitoris BA, Dagher PC, Sandoval RM et al: siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol, 2009; 20: 1754–64
27. Luo J, Nikolaev AY, Imai S et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001; 107: 137–48
28. Kim DH, Jung YJ, Lee JE et al: SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol, 2011; 301: F427–35
29. Wei Q, Dong G, Chen JX et al: Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule-specific knockout mouse models. Kidney Int, 2013; 84: 138–48
30. Deng Y, Wu X, Peig/P3W1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA, 2000; 97: 12050–55
31. Lee SK, Kim YC, Song SB, Kim YS: Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun, 2010; 391: 1592–97
32. Servais H, Ortiz A, Devuyst O et al: Renal cell apoptosis induced by nephrotoxic drugs: Cellular and molecular mechanisms and potential approaches to modulation. Apoptosis, 2008; 13: 11–32
33. Noonan EJ, Place RF, Pookot D et al: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene, 2009; 28: 1714–24
34. Wu J, Bao J, Kim M et al: Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermato genesis. Proc Natl Acad Sci USA, 2014; 111: E2851–57
35. Comazzetto S, Di Giacomo M, Rasmussen KD et al: Oligoasthenoteratozoospermia and infertility in mice deficient for miR-34b/c and miR-449 loci. PLoS Genet, 2014; 10: e1004597
36. Marcet B, Chevalier B, Luxardi G et al: Control of vertebrate multicillogene sis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol, 2011; 13: 693–99

No conflict of interests exists.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]